Quarterly Earnings

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

Core AI divests its cash-burning Siyata Mobile hardware unit just months after merging, betting its future entirely on AI-powered gaming and content.

A deepened strategic alliance sees mobility tech provider ECARX invest in Lotus, aiming to accelerate the future of the intelligent, AI-driven cockpit.

Struggling fashion e-commerce firm MOGU Inc. makes a surprising $14.2M investment in an unnamed AI company, signaling a bold bet on China's tech future.

Twin Hospitality ousts CEO Kim Boerema, naming Chairman Andy Wiederhorn as his replacement to navigate a severe debt crisis and restructure the company.

As Applied Digital preps its Q2 results, investors watch to see if its multi-billion dollar contracts can quell market volatility and affirm its AI future.

National homebuilder Toll Brothers opens Bethany Farms in Simpsonville, tapping into the area's hot luxury market with customizable homes and amenities.

European FinTech Multitude AG unveils its 2026 financial calendar, offering investors a clear roadmap amid strong growth and evolving market dynamics.

Syra Health appoints Gregory R. Alexander as CEO, banking on his military discipline and record of scaling healthcare firms to drive its next growth phase.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

As Simply Good Foods preps its Q1 report, investors weigh Quest's strong growth against the ongoing struggles of its Atkins brand and market pressures.

Riding a wave of record sales from its iDose TR implant, Glaukos is set to update investors on its explosive growth and the launch of its new drug, Epioxa.

Southchip posts its 11th straight quarter of revenue growth, but falling margins and a huge R&D spend reveal a bold, high-risk expansion strategy.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

A new FDA clearance for its AI software enhances Hyperfine's portable MRI, positioning it to disrupt the lucrative stroke diagnostics market. Here's why.

A deep dive into Perma-Pipe's record-breaking quarter, revealing a strategy of regional dominance and savvy diversification into high-growth tech sectors.

Beyond the dividend payout, Cherry Hill Mortgage's strategy reveals a deeper pivot towards digital innovation, balancing high yields with new frontiers of risk.

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.